Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
NASDAQ Granted China SXT Pharmaceuticals, Inc. 180-Day Extension to Regain Compliance with Bid Price Requirement 2020-09-09 21:00
I-Mab Announces Upcoming Participation at September Conferences 2020-09-08 20:00
Executive from Yuyu Pharma Receives Presidential Commendation for Gender Equality Employment 2020-09-04 21:00
I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium 2020-09-04 19:01
AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy 2020-09-04 19:00
111, Inc. Partners with Baiyunshan Pharmaceutical Sales in Digital Medicine Innovation 2020-09-04 18:22
Alphamab Oncology announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to KN046 for the treatment of thymic epithelial tumor 2020-09-03 23:46
PharmAbcine signs a CMO contract with Binex so Binex can produce olinvacimab at its new 5,000L production line 2020-09-02 21:00
Clene Nanomedicine, Inc. to go Public through Merger with Tottenham Acquisition I Limited 2020-09-02 20:00
Innovent Announces First Subject Dosed in the Phase 1 Clinical Trial of Anti-IL-23 Monoclonal Antibody 2020-09-01 08:00
Transcenta Announces First Patient Dosed in Phase I China Trial of Claudin18.2 Targeting Monoclonal Antibody TST001 2020-08-31 23:00
I-Mab Reports Financial Results for the Six Months Ended June 30 and Provides Corporate Update 2020-08-31 19:00
Yiling Pharmaceutical Reports 52.75% YOY Growth in R&D Investment, Boosting the Company's High Quality Development 2020-08-28 18:27
HJB and Ansun Biopharma Enter Strategic Agreement on Biologics CMC Development and Manufacturing Partnership 2020-08-27 23:00
Fosun Pharma Announces 2020 Interim Results 2020-08-26 22:03
RoboPharma Acquired by Capsa Healthcare to Broaden Reach Into New Pharmacy Automation Markets 2020-08-26 08:12
Adlai Nortye Announces First Patient Dosed in Phase 1b Clinical Trial of AN0025 (EP4 Antagonist) in Combination with Merck's KEYTRUDA® (pembrolizumab) for Advanced Solid Tumors 2020-08-24 13:13
111, Inc. Announces Second Quarter 2020 Unaudited Financial Results 2020-08-20 16:35
China Biologic Reports Financial Results for the Second Quarter of 2020 2020-08-18 04:30
I-Mab Announces First Patient Dosed in Phase 1b Study of Plonmarlimab in Rheumatoid Arthritis in China 2020-08-17 20:00
1 116 117 118 119 120 165